Arog Pharmaceuticals is dedicated to developing innovative treatments for rare cancers, with a particular focus on acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GIST). The company’s lead compound, crenolanib, is a selective type I pan-FLT3 inhibitor that targets mutations in the FLT3 gene, which are prevalent in AML patients. Crenolanib has been evaluated in numerous clinical trials, demonstrating its potential to improve outcomes for patients with FLT3 mutations, especially when combined with standard chemotherapy. The company has conducted extensive research, including 16 Phase I-III trials, to assess the safety and efficacy of crenolanib in various patient populations, including those with newly diagnosed and relapsed/refractory AML.

In addition to its focus on crenolanib, Arog Pharmaceuticals has secured exclusive worldwide rights to several patented benzimidazole-based compounds from Pfizer, further enhancing its pipeline of targeted therapies. The company has received multiple designations from the FDA, including Orphan Drug and Fast Track designations, which underscore its commitment to addressing high unmet medical needs in oncology. Arog's strategic approach combines scientific rigor with a patient-centered philosophy, aiming to deliver effective treatments that can significantly improve the quality of life for cancer patients facing challenging diagnoses.

United States

AROG Pharmaceuticals, Inc. was formed to expedite and streamline the transition of early stage molecules into areas of unmet therapeutic needs. We are committed to scientifically validated drug development in collaboration with like-minded investigators and institutions.

Arog Pharmaceuticals

Company Details